Oncology Biomarker Diagnostics

Linking molecular status to breakthroughs in cancer treatment

Assay Menu

MolecularMD employs gold-standard and cutting-edge Technologies & Platforms in creating its high-performance assays. For information about other biomarkers and custom assay design capabilities, contact MolecularMD.

ALK Mutation Testing
BCR-ABL1 Mutation Testing
BCR-ABL1 Quantification Services
BRAF Mutation Testing
c-KIT Mutation Testing
KRAS Mutation Testing
NRAS Mutation Testing
PDGFRa Mutation Testing
Histology and IHC Services 

 

MolecularMD creates the highest quality oncology molecular diagnostics to meets its customers needs, with particular focus in the following areas:

Lung Cancer Targeted Therapy Management

The MolecularMD Clinical Laboratory offers the following sensitive, reproducible and highly specific mutation analysis and expression analysis testing to aid in patient selection for appropriate Lung Cancer Targeted Therapy Management and potential monitoring of treatment efficacy. Download PDF

  • ALK Mutation Analysis (Exons 22, 23, 24, 25)
  • EGFR T790M Plasma Test
  • c-MET Expression Analysis
  • E-cadherin Expression Analysis
  • KRAS Mutation (G12D/A/V/S/R, G13D, Q61L/R/H)
  • Vimentin Expression Analysis
  • Hsp70 Expression Analysis
  • EGFR T790M Resistant Mutation NGx-Profiler 

Melanoma Targeted Therapy Management

The MolecularMD Clinical Laboratory offers the following sensitive, reproducible and highly specific mutation analysis and expression analysis testing to aid in patient selection for appropriate Melanoma Targeted Therapy Management and potential monitoring of treatment efficacy. Download PDF

  • BRAF Mutation Analysis (Exon 15)
  • BRAF Mutation Analysis (V600E/K)
  • NRAS Mutation Analysis (Exons 1,2)
  • NRAS Mutation Analysis (Q61R/K/L)
  • c-KIT Mutation Analysis (Exons 9, 10, 11, 13, 17, 18) 

GIST Targeted Therapy Management

The MolecularMD Clinical Laboratory offers the following sensitive, reproducible and highly specific mutation analysis and expression analysis testing to aid in patient selection for appropriate GIST Targeted Therapy Management and potential monitoring of treatment efficacy. Download PDF

  • c-KIT Mutation Analysis (Exons 9,11,13,17,18)
  • PDGFRa Mutation Analysis (Exons 12,14, 18)
  • c-KIT Expression Analysis 

CML Targeted Therapy Management

The MolecularMD Clinical Laboratory offers the following sensitive, reproducible and highly specific mutation analysis and expression analysis testing to aid in patient selection for appropriate CML Targeted Therapy Management and potential monitoring of treatment efficacy. Download PDF

  • RT-qPCR BCR-ABL1 (p210)
  • RT-qPCR BCR-ABL1 (p190)
  • BCR-ABL1 Mutation Anaysis
  • BCR-ABL1 Mutation NGx-Profiler 

Tumor Suppressor Gene Analysis

The MolecularMD Clinical Laboratory offers the following sensitive, reproducible and highly specific mutation analysis and expression analysis testing to aid in patient selection for appropriate Tumor Suppressor Gene Analysis and potential monitoring of treatment efficacy.  Download PDF

  • LKB1 Mutation
  • PTEN Mutation (Exons 5, 6, 7, 8)
  • PTEN Expression 

PI3K/mTOR Pathway Analysis

The MolecularMD Clinical Laboratory offers the following sensitive, reproducible and highly specific mutation analysis and expression analysis testing to aid in patient selection for appropriate PI3K/mTOR Pathways Analysis and potential monitoring of treatment efficacy. Download PDF

  • PIK3CA Mutation (Exons 1, 5, 7, 9 , 20)
  • PIK3CA Gene Amplification
  • PTEN Expression
  • PTEN Mutation (Exons 5, 6, 7, 8)
  • phospho AKT Ser473 Analysis
  • total AKT Expression Analysis
  • phospho S6 Ser235/236 Analysis
  • phospho S6 Ser240/244 Analysis 

MEK Pathway Analysis

The MolecularMD Clinical Laboratory offers the following sensitive, reproducible and highly specific mutation analysis and expression analysis testing to aid in patient selection for appropriate MEK Pathways Analysis and potential monitoring of treatment efficacy.

  • BRAF Mutation (Exon 15)
  • BRAF Mutation (V600E/K)
  • KRAS Mutation (G12D/A/V/S/R, G13D, Q61L/R/H)
  • NRAS Mutation (Exons 1, 2)
  • NRAS Mutation (Q61R/K/L)
  • phospho ERK Thr202/Tyr204 Analysis

Oncology Thought Leaders Series:
Brian Druker, MD speaks on the value of
companion diagnostics in patient outcomes